Skip to main content

06-12-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

Conference coverage direct to your inbox
John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

More on this topic

Back to the conference hub

Related topics

Image Credits